Skanditeks subsidiary CMA Microdialysis AB launches system for continuous bedside glucose monitoring

Skanditeks subsidiary CMA Microdialysis AB launches system for continuous
bedside glucose monitoring

CMA Microdialysis AB (CMA) today announced the launch of the new CE-approved
IView Catheter,
which enables highly accurate tight glycemic control (TGC) in the Intensive Care
Unit (ICU).

Skanditek holds 78 percent of it´s subsidiary CMA Microdialysis.

As to the rest, we refer to enclosed press release from CMA Microdialysis AB.


SKANDITEK INDUSTRIFÖRVALTNING AB (publ)


For further information, please contact:

Patrik Tigerschiöld, President and CEO,
telephone +46-8-614 00 20,

Philip Siberg, CEO CMA Microdialysis,
mobil +46 70 790 67 43, e-post philip.siberg@microdialysis.se

Skanditek is an industrial holding company owning stock in Swedish companies.
The business concept is to be an active and long-term stockholder and to further
the portfolio companies' development by providing industrial and financial
competence at board and management level. The portfolio comprises 9 companies
within technology, biotechnology and services. The major holdings are in Bure
Equity (17%), MYDATA automation (95%), PartnerTech (36%),and Vitrolife (25%).
Skanditek is listed on the OMX Nordic List.